BASF Sounds Out Evonik Takeover as RAG-Stiftung Holds the Deciding Lever

BASF confirms exploratory talks with Evonik and RAG-Stiftung over a possible voluntary public takeover offer; Evonik shares closed 7.9% higher at EUR 19.44.

BASF has confirmed exploratory talks with Evonik Industries AG and the RAG-Stiftung over a possible voluntary public takeover offer, a move that instantly reshaped the investment case for the Essen-based specialty chemicals maker and put its anchor shareholder at the centre of the story.

Evonik disclosed on Friday that it had received an unsolicited approach from the Ludwigshafen group regarding an offer for all of its shares. The stock closed the session 7.9% higher at EUR 19.44, having touched its 52-week high of EUR 20.00 at one point during the day. Reports of the approach, first carried by Reuters, described the proposal as non-binding, with BASF stating that the outcome of the soundings remains entirely open. Evonik, for its part, made clear that no talks are currently being held between the parties.

The RAG-Stiftung, which owns 44% of Evonik, will effectively determine whether any transaction advances. No public signal has yet emerged on whether the foundation would be prepared to sell or contribute its stake — a decision that touches not only economic criteria but also its long-term charitable objectives and regional policy interests in North Rhine-Westphalia. Without the anchor investor's explicit consent, a merger or takeover against the will of Evonik's management is unthinkable. The same applies to the company's own board: because no negotiations are under way, BASF would have to take the initiative and dangle financial incentives to bring directors to the table.

A transaction premium now competes with an operational overhaul

For shareholders, the arrival of BASF changes the framework fundamentally. Until now, the operational restructuring dominated the narrative; a potential deal premium now drives sentiment. The key question for investors is whether to lock in the gains accumulated so far or hold on in the hope of further upside.

Should the soundings lead to concrete negotiations, additional potential opens up. A voluntary public takeover offer is typically pitched at a noticeable premium to the unaffected average price, and BASF would need to present terms that economically outbid Evonik's standalone prospects and its ongoing cost-cutting. The company recently fleshed out the second phase of its transformation programme, dubbed "Evonik Tailor Made", which envisages cutting 3,200 jobs worldwide between 2027 and 2029, around 2,150 of them in Germany. Alongside that, Evonik is pushing ahead with the disposal of peripheral activities, with the sales of infrastructure company Syneqt GmbH and the C4 chemicals business Oxeno GmbH proceeding as planned. Executed swiftly, those portfolio moves could allow the group to bring markedly stronger earnings power to the table even in the event of a merger.

Sell-side caution preceded the approach

Before news of the BASF discussions surfaced, analysts had taken a measured view of Evonik's prospects. Morgan Stanley downgraded the stock to "Equal-weight" from "Overweight" on 15 September and trimmed its price target to EUR 18 from EUR 21. JPMorgan had already stuck with a sell recommendation on 11 September, citing the burden of rising energy costs.

Those concerns have not disappeared. If the approach collapses, the takeover speculation could drain out of the share price abruptly, forcing the stock to be measured once again against the pure fundamentals of the European chemicals sector — still characterised by high energy costs, geopolitical uncertainty and hesitant demand. A sharp retreat to pre-deal levels would be the immediate consequence of a declared end to talks. Traders had already assessed the probability of an actual transaction sceptically when the first reports of interest emerged.

Even a friendly agreement would carry substantial execution risk. A combination of two industry heavyweights would inevitably draw in European competition authorities, and months of review, stringent conditions or an outright veto could weigh on the deal and block the valuation premium for an extended period.

Restructuring runs in parallel

The takeover soundings land in the middle of deep operational cuts at the Essen group. On 22 September, Evonik announced the worldwide reduction of 3,200 positions as part of its restructuring programme, 2,150 of which fall at German sites. Media reports also point to the closure of smaller operating locations in Hamburg and Bitterfeld, which the company had already flagged on 11 September. The savings and restructuring plan is designed to lower the cost base and recalibrate the group's set-up, while management must now simultaneously weigh the advances from Ludwigshafen.

What to watch next

The next concrete catalyst is an official statement from BASF or the RAG-Stiftung on the start — or definitive end — of formal talks. Details on progress with the Oxeno and Syneqt disposals are also likely to set direction. Until then, the decisive factor is whether the shares can defend the level marked in recent days, which would signal that the market is pricing in a realistic chance of agreement. A formal rejection from the RAG-Stiftung, by contrast, would probably trigger a rapid unwinding of the recent gains.

Fresh insight into operating performance arrives in a few weeks: Evonik will publish its financial report for the third quarter of 2026 on 3 November 2026. Until then, the progress of the BASF soundings and the stance of the RAG-Stiftung are likely to stay firmly in investors' sights.